Watch: Cracking the Cancer Code
Cancer is a very complex set of diseases. It’s 30 or 40 different diseases with hundreds of indications. How can we more rapidly bring drugs to market to benefit patients?
You need: Good Science The Right Patients Operational Smarts Market Insights
New Health Library
Early Phase
-
Mapping the Future in Oncology Drug Development
Maximize drug development for optimal patient treatment.
-
Advancing Oncology Care Through Innovative Treatment Approaches
Shaping future treatment paradigms to improve patient survival.
-
Integration of Molecular Biomarkers into Clinical Development
Biomarkers to confirm a drug’s mechanism of action
-
From Biomarkers to Diagnostics - The Road to Success
Assess the passage from biomarker candidate to diagnostic entity
-
Biomarker Trends in Breast Cancer Research
Implications and questions that will drive future R&D efforts
-
The Molecular Biomarker Revolution in Non-Small Cell Lung Cancer
Advances in understanding the molecular basis of NSCLC
-
CardioCheck: A Biomarker Assay Program
Rapid insight into potential cardiotoxic influences
-
Translational R&D Services Fact Sheet
Providing a range of solutions to help maximize success
Drug Development
-
Key Trends in Multiple Myeloma Treatment
Producing new treatment approaches - giving physicians and patients more options
-
Oncology Expertise - Scientific Collaborator for Global Solutions
Lab solutions critical for successful oncology drug development
-
Management of Tissue Specimens for Oncology Drug Development in China
Download presentation from the Clinical Development of Cancer Drugs in China (CSCO)
-
A Blueprint for Clinical / Commercial Convergence
Suggestions on how to develop and deploy a “Clinical-Commercial Product Blueprint”
-
Responsive Recruitment - Nimble Strategies for Changing Protocol
Demonstrated ability to quickly adapt to changing circumstances
-
Recruiting Trust - Cancer Trial Enrollement Twice as Fast as Projected
Robust presence, local knowledge and extensive scientific ensured milestones were met
-
Strategic Response - Global Flexibility, Expertise and Network Avert Delays
Geographical presence, previous experience in oncology, and a study team comprised of professionals
Commercialization
-
Oncology Drug Development and Value-Based Medicine
Need to converge clinical and commercial imperatives earlier within the drug development process to meet a future demand
-
Rapid Deployment - Oncology MSL Team Exceeds Expectations
Quintiles provided the sponsor with a high degree of flexibility by transitioning the old and new teams
-
New Voices and New Opportunities Toward Patient-Centric Model
Biopharmaceutical companies must learn to navigate the increasingly tricky waters of commercializing products
-
Market Intelligence and Analytics for Oncology
Helping biopharma get a 360-degree view of their challenges and opportunities
-
Commercial – Identify, Promote and Prove Treatment Value
An unmatched suite of commercial competencies
- Product Solutions - Partnering for Convergence Success
- Demonstrating Product Values
- Oncology Nurse Educators - Groundbreaking Lessons
-
Quintiles and Outcome
Real-world and Late Phase Research
